six times the head of aetna insurance, six times the head of pfizer drug, have met with him in the white house. he's never called out to us. >> hinojosa: has he called out to you? >> never once. doesn't answer the letters. one of his best friends, dr. quentin young, 85 years old, in chicago, the leader of the single payer movement, wonderful doctor who he used to spend quite a bit of time with, he never invites him for consultation. the head of aetna, the source of the problems? he is conflict averse. >> hinojosa: so what do american citizens... what do we do, then? because, you know, there are a lot of people who are saying, "well, wait a second. we thought that change was on the way." obviously some people are saying, "wait a second. we don't see the change coming. now i feel entirely frustrated, and i feel so frustrated that i'm entirely apathetic, and i don't want to do anything." >> well, that's exactly what the power structure wants you to do. in other words, wants you to quit, to withdraw. and of course, that is not acceptable, right, if you care for your descendants and your chil

pfizer the drug company. great. the innovation in medication today is phenomenal. pfizer are producing amazing drugs. but again, tainted by this issue of i will call it cronyism, but there is a deeper issue. one quick example. i used to work at the institute for justice. you probably heard about the issue of eminent domain abuse. i'm hoping you heard about the kilo case in connecticut where suzette kilo's home was taken through eminent domain and handed over with hundreds of other homes to a developer so he could build a company partly which would be used by pfizer. so in my view that taints pfizer in a sense. if you think about the circumstances of this, we knocked hundreds of homes down and ultimately it is like nine years later, and what we have to show for it? not that we should expect good things out of this arrangement, but what we have to show for it is a barren field that isn't being used by anybody because it's stuck in all sorts of fights over it except ironically literally a group -- a group of cats. just a bunch of cats, and they are not even fat-cats. t

drug worked for kids and biogen. >>> seeing some unusual volume in abbott labs. >> earlier in the day pete talked about unusual activity in pfizert unusual activity in another drug stock, abbott. this one, the yield is a little lower than pfizer. it's about a 2% yielder. but they were buying upside calls. the stock has made a nice little move. and in particular, they're buying the december 46 calls a lot more than the open interest, which tests says are establishing new open positions. they're betting the stock trades higher in the short-term because they could be throughout in a january time frame like mr. yee was saying just now for some of the big health care conferences that come around in that time. but instead, they're here in december. so they think this happens like that. i bought it today. >> all right. coming up next, the chinese smartphone manufacturer that just might be giving apple a serious run for its money. >>> and later, president obama wants to see more cops wearing cameras in hopes of building the trust between the public and police. >>> and the proposal shares of taser moving higher, to a new high today. we s

nike, pfizer and merck. drug stocks. drugs, you know, some of the traditional.n plays going higher. >> worst three are boeing, exxon and jpmorgan. caterpillar, too. bob pisani, do you think it's the same story today? >> very sensitive of two issues. one is decline of oil and collateral damage of that and second is slower growth concerns overall. so we have 52-week lows all over the place in the energy place, chevron, for example in the dow. some of the exploration names and drillers all at 52-week lows. a lot of collateral damage and the canadian banks, bank of nova scotia. they're involved in financing. all weaker today. commodity countries are hit on the lower growth concerns out there so exchange traded funds around russia, for example, south africa, canada, all co commodity countries all down 2% or so. commodity stocks are also on the 52-week low list right now and iron ore names. all in down 2% to 4%. slower growth in china and a crackdown on gambling? 52-week lows even in the casino names. las vegas sands and wyndham in the china market and lower here. air

sold teva -- sold big short interest in the stock, pfizer made a big investment in the drug, i have friendsf mine, people that invested in like gen and stuff like that. sair ris and stuff like that. w that whole space it's a lottery ticket. if you buy enough in the space that has momentum and diversify out you will make money. >> you own the stock yourself personally. >> yep. >> i don't know if you have an opinion of this one or follow it. the fact that the ibb is up almost 40% year to date. the message of the market the momentum of certain spaces within this market, do they continue to work like biotech? >> i think they do, but to mark's point, one of the reasons you want that diversity, too, is that you've got gilead today, just being taken out to the woodshed on the express description saying we're not going to support them and the hepatitis c treatment because it's too expensive. that hurt dendrian and when you a break through drug you have to price it right. if you price it too high some of the guys can run away. >> to get a high quality, large cap biotech on sale down 13%. >> your poi

a drug aiming to do the same thing from pfizer and johnson & johnson although in a slightly different way. bigensays it plans to move aggressively into final trades of clinical trials. the company said it will continue exploring additional doses. there is cautious optimism and potentially good news for more than 5 million americans with alzheimer's. a big market means a big business opportunity. deutsche bank estimates success in alzheimer's could mean up to $5 billion in annual revenue for bio gen. >> thank you so much. the stock up about 6%. >>> the count down to christmas, only 22 days, 10 hours, 51 minutes and 36 seconds, dominic chu, for you to get my gift. >> i know what i'm getting you. >> that's good. >> get ready to be surprised. >> you did a screen looking at which stocks of the retail companies that are part of the etf do best between thanksgiving and christmas. tell us how and who? >> we talked to partners. we said let's take a look at these stocks. there is about 100 stocks in the retail universe in this particular etf. 100 components of the xrt, we looked at the 20 tradi

drugs are starting to show promise. >> most traditional doctors i know are afraid to actually write a script for medical marijuana, into you it's different place to place. why isn't a pfizerr bristol-myers doing what you're doing? >> that's why we exist. the dilemma that physicians and patients face is the option that's available now in certain states doesn't allow for a control source with the safeguards that an fda approve provides. that's what gw role we can play. we have real medicines that are prescribed, reimbursed and the patient can trust that we know exactly what's in it. >> i agree. i was surprised when the american cad me of neurology said that medical marijuana is the real thing. from the 5th to the 9th, a lot of people are saying cramer, the stock is up, is it possible you might have some breakthrough things that might be announced. >> there are a lot of events around the society. i would say the data coming out there is subsets of data, which has already been seen by investors. more color around that meeting. and i think the excitement is undoubtedly something that will be important for or company, not just this year, but of course going into medical meeting

today signs a deal with pfizer $295 million up front payment for long acting human growth hormone. this not a primary drug to be something that phil's had. i think phil is so bankable, a lot of charity, if you go to the "u," you know phil's there, i've always -- i think he's a great guy. bought a ton of stock here. always said he had something. looks like he does. congratulations. the stock's going higher. >> all right. >> they have a lot of drugs about different kinds of cancers and detection. >> i know. taken me back to last week's deal with cubist and merck, i don't know why i thought of that. >> people are saying cubist isn't trading, it's not where it should be than deal was etched in stone. >> carved out of the merger agreement any bad decision, which they got immediately on cubism. >> that's not true. there was at least six hours between when they bought it and discovered it was worth a lot less, maybe seven. >> shocking. >> how about with -- can we hack into their e-mails? >> whose. >> frazier, merck's. >> i don't think we should do that. stay away. opening bell a few minutes from now. >>> we'll h